377 - Impact of VE303, a Defined Bacterial Consortium, on Antimicrobial Resistant Gene Prevalence in Patients with Clostridioides difficile Infection (CDI)

Friday, October 18, 2024

1:57 PM - 2:09 PM US PT

Location: 403 A

Presenting Author(s)

EC

Emily Crossette, PhD

Scientist
Vedanta Biosciences
Somerville, Massachusetts, United States
SB

Shakti Bhattarai, PhD

UMASS Chan Medical School
368 Plantation St, Massachusetts, United States
VB

Vanni Bucci, PhD

UMass Chan Medical School
Worcester, Massachusetts, United States
MK

Marlena Keisler, n/a

Vedanta Biosciences
Cambridge, Massachusetts, United States
Gregory Medlock, PhD

Director, Research
Vedanta Biosciences
Cambridge, Massachusetts, United States
BO

Bernat Olle, PhD

CEO
Vedanta Biosciences
Cambridge, MA, United States
JS

Jeffrey L. Silber, MD

Chief Medical Officer
Vedanta Biosciences
Cambridge, Massachusetts, United States
JN

Jason Norman, PhD

Associate Director
Vedanta Biosciences
Cambridge, MA, United States

Disclosure(s):

Rajita Menon, PhD: Vedanta Biosciences: Employment, Patent inventor, Stocks/Bonds (Private Company)

Emily Crossette, PhD: Vedanta Biosciences: Employment, Stocks/Bonds (Private Company)

Shakti Bhattarai, PhD: No financial relationships to disclose

Vanni Bucci, PhD: Vedanta Biosciences: Advisor/Consultant

Marlena Keisler, n/a: Vedanta Biosciences: Employer

Gregory Medlock, PhD: Vedanta Biosciences: Ownership Interest

Bernat Olle, PhD: Vedanta Biosciences, Inc.: Board Member, Ownership Interest, Stocks/Bonds (Private Company)

Jeffrey L. Silber, MD: Vedanta Biosciences: Employee, Ownership Interest

Jason Norman, PhD: Vedanta Biosciences: Employment, Patent inventor, Stocks/Bonds (Private Company)